Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 26,862	$ 3,177
Prepaid expenses and other current assets	759	1,092
Total current assets	27,621	4,269
Property and equipment, net	154	174
Right-of-use assets, net	351
Deposits and other assets	19	17
Total assets	28,145	4,460
Current liabilities:
Accounts payable	1,607	486
Accrued expenses	1,220	875
Accrued compensation expense	199	173
Accrued clinical trial expenses	1,212	1,063
Current operating lease liabilities	167
Current debt	2,200	2,200
Contract liabilities	335	335
Total current liabilities	6,940	5,132
Long term operating lease liabilities	199
Total liabilities	7,139	5,132
Commitments and contingencies
Stockholders’ equity (deficit):
Preferred stock, no par value, 10,000 shares authorized; none outstanding
Common stock, no par value; 300,000 shares authorized; shares issued and outstanding: 27,908 and 23,214 as of March 31, 2021 and December 31, 2020, respectively	294,592	270,126
Additional paid-in capital	49,333	49,314
Accumulated other comprehensive loss	(412)	(448)
Accumulated deficit	(322,507)	(319,664)
Total stockholders’ equity (deficit)	21,006	(672)
Total liabilities and stockholders’ equity (deficit)	$ 28,145	$ 4,460